atorvastatin

Atorvastatin is an orally active HMG-CoA reductase inhibitor that has the ability to effectively lower blood lipids by activating liver cytochrome p450 to accelerate metabolism. Atorvastatin inhibited proliferation and invasion of human SV-SMC cells with IC50 values of 0.39 μM and 2.39 μM, respectively. Atorvastatin combined with clopidogrel may lead to increased thrombotic events in patients.

Atorvastatin Sodium (Lipitor) is a competitive inhibitor of HMG-CoA reductase and increases the expression of low density lipoprotein (LDL) receptors on hepatocytes. Atorvastatin Sodium treatment inhibits aquaporin 4 to reduce ischaemic brain oedema.

2-Hydroxy atorvastatin calcium salt is a hydroxy metabolite of Atorvastatin calcium salt which is a potent HMG-CoA reductase inhibitor (IC50 = 8 nM).

Desfluoro-atorvastatin is an Atorvastatin impurity. Atorvastatin is an orally active inhibitor of HMG-CoA reductase. It has the ability to effectively decrease blood lipids.

2-Hydroxy atorvastatin lactone, a metabolite of Atorvastatin, is an orally active HMG-CoA reductase inhibitor that efficiently reduces blood lipids [1][2].

Difluoro atorvastatin is an Atorvastatin impurity. Atorvastatin is an orally active HMG-CoA reductase inhibitor and it has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion (IC50s: 0.39 μM and

4-hydroxy Atorvastatin is a metabolite of atorvastatin , an HMG-CoA reductase inhibitor present in formulations that have been used to treat hypercholesterolemia and certain dyslipidemias. Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin.

ortho-Hydroxy Atorvastatin-d5 Calcium Salt is a deuterated compound of ortho-Hydroxy Atorvastatin Calcium Salt. ortho-Hydroxy Atorvastatin Calcium Salt has a CAS number of 265989-47-7.

Atorvastatin Epoxy Tetrahydrofuran Impurity is an impurity isolated oxidative degradation products of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor.

Atorvastatin acetonide is an impurity of Atorvastatin. Atorvastatin is an HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

O-Methyl Atorvastatin is an impurity of Atorvastatin that is an orally active inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, has the ability to effectively decrease blood lipids.

3-Oxo Atorvastatin is an impurity of Atorvastatin. Atorvastatin is an HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

Atorvastatin acetonide tert-butyl ester is a useful pharmaceutical intermediate in the preparation of Atorvastatin salts. Atorvastatin is an HMG-CoA reductase inhibitor.

Atorvastatin Hemicalcium Trihydrate, an orally active HMG-CoA reductase inhibitor, effectively reduces blood lipids. It also inhibits human SV-SMC proliferation and invasion, showing IC50 values of 0.39 μM and 2.39 μM, respectively.

Atorvastatin strontium is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia.

para-Hydroxy Atorvastatin-d5 Calcium Salt is a deuterated compound of para-Hydroxy Atorvastatin Calcium Salt. para-Hydroxy Atorvastatin Calcium Salt has a CAS number of 214217-88-6.

(3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

Atorvastatin magnesium trihydrate is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia.

ortho-Hydroxy Atorvastatin-d5 Lactone is a deuterated compound of ortho-Hydroxy Atorvastatin Lactone.

Atorvastatin magnesium is an HMG-CoA inhibitor.

ent-Atorvastatin is a selective and competitive inhibitor of HMGCR (HMG-CoA reductase).

Atorvastatin, (3S,5R)- is an Atorvastatin impurity.

Atorvastatin ethyl ester, a derivative of Atorvastatin, exhibits potent inhibition of 9-cis-RA-induced Gal4 reporter activity.

Atorvastatin methyl ester is a derivative of Atorvastatin. It inhibits the 9-cis-RA-induced Gal4 reporter activity more strongly than Atorvastatin.

Atorvastatin-d5 Calcium Salt is a deuterated compound of Atorvastatin Calcium Salt. Atorvastatin Calcium Salt has a CAS number of 134523-00-5.

Atorvastatin lactone is a prodrug form of atorvastatin. Which is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Atorvastatin 3-Deoxyhept-2E-Enoic Acid is an impurity of Atorvastatin. Atorvastatin is an HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

Atorvastatin hemicalcium salt (Atorvastatin Calcium), an effective HMG-CoA reductase inhibitor (IC50 = 8 nM), is utilized as a cholesterol-lowering medication.

Atorvastatin is used to inhibits HMG-CoA reductase for lowering blood cholesterol and for prevention of events associated with cardiovascular disease.

Atorvastatin lysine is a selective and competitive HMGCR (HMG-CoA reductase) inhibitor.

MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin in rabbits, dogs and monkeys. MB-07344 is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM.

MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model. |1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96(9), 2889-2897 (2011).|2. Haczeyni, F., Wang, H., Barn, V., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1(7), 663-674 (2017).

LAU-0901, a platelet-activating factor (PAF) receptor antagonist, demonstrates efficacy in reducing infarct volume and enhancing neurological function in rats subjected to middle cerebral artery occlusion (MCAO)-induced cerebral ischemia, at doses of 30, 60, and 90 mg/kg. Furthermore, it diminishes microglial infiltration while promoting astrocytic and neuronal survival in the same model. Additionally, at a dose of 30 mg/kg, LAU-0901, either alone or combined with atorvastatin, shows a capability to inhibit tumor growth in a U87MG glioblastoma mouse orthotopic tumor model.

MB-07344 sodium has additive cholesterol lowering activity in combination with Atorvastatin in rabbits, dogs and monkeys. MB-07344 sodium is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM.

NCX-6560 is a novel NO-releasing derivative of atorvastatin, with those of atorvastatin. NCX-6560 inhibits cholesterol biosynthesis in rat smooth muscle cells with an IC50 of 1.9 μM.

Setipafant is an antagonist of the platelet-activating factor.